SignalXSignalX

NUVL Nuvalent, Inc.

Q3 2025 10-Q
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Nuvalent, Inc. Overview

Nuvalent, Inc. (NUVL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Need for capital beyond current cash runway into 2028 triggered by advancing zidesamtinib, neladalkib, NVL-330, and discovery programs
  • • Updated risk: Net losses increased to $306.7M for nine months ended Sept 30, 2025, vs $260.8M for 2024, reflecting higher R&D and commercialization prep costs
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$122M

▼ -45.2% YoY▼ -22.9% QoQ

ROE

-14.5%

Total Assets

$980M

EPS (Diluted)

$-1.70

▼ -31.8% YoY▼ -22.3% QoQ

Operating Cash Flow

-$70M

▼ -53.8% YoY▲ +8.0% QoQ

Source: XBRL data from Nuvalent, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Nuvalent, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.